阿德福韦酯治疗失代偿期乙型肝炎肝硬化的疗效及安全性

摘要

Objective:To analyze the efficacy and safety of Adefovir Dipivoxil for decompensated cirrhosis.Method:98 cases of decompensated cirrhosis were randomly divided into observation group and control group according to the method of randomization.The control group was received Lamivudine for the treatment and the observation group was received Adefovir Dipivoxil for the treatment.The liver function improvement,HBV-DNA and e-antigen seroconversion rate and the implications of the two groups were observed.Result:The liver function improvement of the observation group were better than those of the control groups(P<0.05).And the HBV-DNA and e-antigen seroconversion rate of the observation group at 48 weeks and 96 weeks were better than those of the control groups(P<0.05).Conclusion:Adefovir Dipivoxil in the treatment of decompensated cirrhosis can improve the patient’s liver function,improve the HBV-DNA and e-antigen seroconversion rate,which is safty for clincil application.%目的：探讨阿德福韦酯对失代偿期乙型肝炎肝硬化患者的临床治疗效果。方法：按照随机分组的方法将98例失代偿期乙肝肝硬化患者分为对照组和治疗组，对照组给予拉米夫定片治疗，观察组给予阿德福韦酯胶囊治疗。比较两组肝功能改善情况、HBV-DNA和e抗原转阴率及不良反应发生情况。结果：治疗后观察组TBiL、ALT及AST改善情况均优于对照组，两组比较差异有统计学意义(P<0.05)。观察组治疗后第48周和96周HBV-DNA和e抗原转阴率均优于对照组，两组比较差异有统计学意义(P<0.05)。阿德福韦酯治疗期间，未发现明显不良反应，所有患者均能耐受治疗。结论：阿德福韦酯可较好的改善失代偿期乙型肝炎肝硬化患者的肝功能，提高HBV-DNA和e抗原转阴率，具有较好的安全性，值得临床推广应用。